RHBDL2

Across TCGA pan-cancer cohorts, RHBDL2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RHBDL2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RHBDL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RHBDL2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where RHBDL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.362	0.857	.005	15	view →
HNSC	OS	Quartile	All	1.000	0.259	.024	10	view →
LUAD	DFS	Median	All	0.980	0.875	.004	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RHBDL2–CCRCC (DFS)

Open the CCRCC breakdown →